Σάββατο 29 Δεκεμβρίου 2018

Development of A Core Outcome Set For Infant Gastroesophageal Reflux Disease

Objective: In therapeutic trials for infant gastroesophageal reflux disease (GERD), ways to define GERD and measure and report study outcomes vary widely. The aim of this study was to develop a core outcome set (COS) for infant GERD. Methods: The COS was developed using the Delphi technique, adhering to the OMERACT 2.0 recommendations. Healthcare professionals (HCPs) (predominantly pediatric gastroenterologists and general pediatricians) and parents of infants (age 0–12 months) with GERD, listed up to five primary goals of therapy from their perspective and up to five persistent signs or symptoms that would signify inadequate treatment. Outcomes mentioned by >10% of participants were included in two shortlists. Next, HCPs and parents rated and prioritized outcomes on these shortlists. Outcomes with the highest rank formed the draft COS. The final COS was created after two consensus meetings between an expert panel and patient representatives. t In total, 125/165 HCPs (76%) and 139/143 parents (97%) of infants with GERD completed the first phase. The second phase was completed by 83/139 HCPs (60%) and 127/142 different parents (89%). Outcomes of these phases were discussed during the consensus meetings and a 9-item COS was formed: "Adequate Growth," "Adequate Relief," "Adverse events,", "Crying," "Evidence of Esophagitis," "Feeding Difficulties," "Hematemesis," "No Escalation of Therapy," and "Sleep Problems". Conclusions: We developed a COS for infant GERD consisting of 9 items that should minimally be measured in future therapeutic trials to decrease study heterogeneity and ease comparability of results. Address correspondence and reprint requests to Merit M. Tabbers, MD, PhD, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, H7-250, PO Box 22700, 1100 DD Amsterdam, The Netherlands (e-mail: m.m.tabbers@amc.nl) Received 12 December, 2018 Accepted 12 December, 2018 Supplemental digital content is available for this article. Direct URL citations appear in the printed text, and links to the digital files are provided in the HTML text of this article on the journal's Web site (www.jpgn.org). Maartje M.J. Singendonk and Robyn Rexwinkel Indicates shared first authorship Funding source: This study was funded by a Networking Grant from the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). Financial disclosure: The authors have no financial relationships relevant to this article to disclose. Conflict of interest: The authors have no conflicts of interest relevant to this article to disclose. Disclaimer: Although this paper is produced by the ESPGHAN Motility Working group, it does not necessarily represent ESPGHAN policy and is not endorsed by ESPGHAN. Disclaimer: Although this paper is produced by the ESPGHAN Motility Working group, it does not necessarily represent ESPGHAN policy and is not endorsed by ESPGHAN. Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (www.jpgn.org). © 2018 by European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology,

from Gastroenterology via xlomafota13 on Inoreader http://bit.ly/2CFJlfL
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.